SG11201510816SA - Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist - Google Patents
Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonistInfo
- Publication number
- SG11201510816SA SG11201510816SA SG11201510816SA SG11201510816SA SG11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA SG 11201510816S A SG11201510816S A SG 11201510816SA
- Authority
- SG
- Singapore
- Prior art keywords
- mrna
- gene expression
- cancer therapy
- based gene
- patient cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842567P | 2013-07-03 | 2013-07-03 | |
| US201361912781P | 2013-12-06 | 2013-12-06 | |
| PCT/EP2014/064039 WO2015000945A1 (fr) | 2013-07-03 | 2014-07-02 | Expression génique à base d'arnm pour la personnalisation de la thérapie anticancéreuse d'un patient par un antagoniste de mdm2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510816SA true SG11201510816SA (en) | 2016-01-28 |
Family
ID=51162759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510816SA SG11201510816SA (en) | 2013-07-03 | 2014-07-02 | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3017061B1 (fr) |
| JP (2) | JP6461126B2 (fr) |
| KR (1) | KR101879926B1 (fr) |
| CN (1) | CN105378112B (fr) |
| AU (1) | AU2014286237B2 (fr) |
| BR (1) | BR112015031542A2 (fr) |
| CA (1) | CA2912547A1 (fr) |
| HK (1) | HK1215453A1 (fr) |
| IL (1) | IL242692B (fr) |
| MX (1) | MX363584B (fr) |
| RU (1) | RU2016101514A (fr) |
| SG (1) | SG11201510816SA (fr) |
| WO (1) | WO2015000945A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| EP2819688A4 (fr) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | Macrocycles peptidomimétiques réticulés par triazole et par thioéther |
| JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス，インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
| JP2017508442A (ja) * | 2014-01-14 | 2017-03-30 | 第一三共株式会社 | Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー |
| EP3197477A4 (fr) | 2014-09-24 | 2018-07-04 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et formulations de ceux-ci |
| CA2961258A1 (fr) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Macrocycles peptidomimetiques et leurs utilisations |
| US20170283885A1 (en) * | 2014-10-09 | 2017-10-05 | Daiichi Sankyo Company, Limited | Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors |
| CA2976752C (fr) | 2015-02-20 | 2019-12-17 | Daiichi Sankyo Company, Limited | Polytherapie pour traiter un cancer |
| CN107614003A (zh) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP6848047B2 (ja) * | 2016-08-08 | 2021-03-24 | フェイ シアオ， | スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用 |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2020018611A1 (fr) * | 2018-07-18 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes d'identification, d'évaluation, de prévention et de traitement d'un sarcome d'ewing à l'aide de biomarqueurs et de modulateurs de la dépendance de tp53 |
| KR20180093849A (ko) | 2018-08-09 | 2018-08-22 | 가톨릭대학교 산학협력단 | 줄기세포 사멸 예측 마커 및 이의 용도 |
| WO2020124043A1 (fr) * | 2018-12-13 | 2020-06-18 | Gordon Erlinda M | Procédés d'exploitation d'oncogènes pilotes le long de la voie biologique de la cycline g1 humaine pour thérapie génique du cancer |
| KR20190060964A (ko) | 2019-05-24 | 2019-06-04 | 가톨릭대학교 산학협력단 | 줄기세포 사멸 예측 마커 및 이의 용도 |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| EP4204812A2 (fr) * | 2020-08-27 | 2023-07-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarqueurs pour la thérapie anticancéreuse utilisant des antagonistes de mdm2 |
| RU2766739C1 (ru) * | 2021-04-12 | 2022-03-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ прогноза эффективности терапии меланомы |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050064455A1 (en) * | 2003-05-28 | 2005-03-24 | Baker Joffre B. | Gene expression markers for predicting response to chemotherapy |
| CN101316823B (zh) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| ES2482692T3 (es) * | 2008-05-12 | 2014-08-04 | Genomic Health, Inc. | Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia |
| BRPI0919325A2 (pt) | 2008-09-18 | 2021-03-30 | F.Hoffmann-La Roche Ag | Pirrolidina-2-carboxamidas substituídas |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-07-02 JP JP2016522593A patent/JP6461126B2/ja not_active Expired - Fee Related
- 2014-07-02 WO PCT/EP2014/064039 patent/WO2015000945A1/fr active Application Filing
- 2014-07-02 CN CN201480037933.6A patent/CN105378112B/zh not_active Expired - Fee Related
- 2014-07-02 SG SG11201510816SA patent/SG11201510816SA/en unknown
- 2014-07-02 KR KR1020157037051A patent/KR101879926B1/ko active IP Right Grant
- 2014-07-02 BR BR112015031542A patent/BR112015031542A2/pt not_active IP Right Cessation
- 2014-07-02 MX MX2015018051A patent/MX363584B/es unknown
- 2014-07-02 EP EP14736727.0A patent/EP3017061B1/fr not_active Not-in-force
- 2014-07-02 RU RU2016101514A patent/RU2016101514A/ru not_active Application Discontinuation
- 2014-07-02 AU AU2014286237A patent/AU2014286237B2/en not_active Expired - Fee Related
- 2014-07-02 CA CA2912547A patent/CA2912547A1/fr not_active Abandoned
-
2015
- 2015-11-19 IL IL242692A patent/IL242692B/en active IP Right Grant
-
2016
- 2016-03-23 HK HK16103385.9A patent/HK1215453A1/zh unknown
-
2018
- 2018-11-05 JP JP2018207947A patent/JP2019059737A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL242692B (en) | 2019-12-31 |
| WO2015000945A1 (fr) | 2015-01-08 |
| JP2019059737A (ja) | 2019-04-18 |
| KR101879926B1 (ko) | 2018-08-16 |
| JP2016529880A (ja) | 2016-09-29 |
| AU2014286237B2 (en) | 2020-08-20 |
| CN105378112A (zh) | 2016-03-02 |
| HK1215453A1 (zh) | 2016-08-26 |
| MX363584B (es) | 2019-03-27 |
| JP6461126B2 (ja) | 2019-01-30 |
| BR112015031542A2 (pt) | 2017-07-25 |
| EP3017061B1 (fr) | 2019-01-02 |
| MX2015018051A (es) | 2016-03-16 |
| RU2016101514A3 (fr) | 2018-05-28 |
| CA2912547A1 (fr) | 2015-01-08 |
| CN105378112B (zh) | 2020-10-13 |
| AU2014286237A1 (en) | 2016-01-28 |
| EP3017061A1 (fr) | 2016-05-11 |
| KR20160013214A (ko) | 2016-02-03 |
| RU2016101514A (ru) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242692B (en) | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist | |
| IL245731A0 (en) | Combined treatment for cancer | |
| GB201322725D0 (en) | Cancer therapy | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| EP2968343A4 (fr) | Polythérapie pour traiter un cancer | |
| HK1201755A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1205691A1 (en) | Dual ox40 agonist/il-2 cancer therapy methods ox40 /il-2 | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1220900A1 (zh) | 癌症的治療 | |
| HK1214611A1 (zh) | 作為癌症治療和診斷靶標的 | |
| EP2994148B8 (fr) | Thérapie du cancer | |
| LT3077544T (lt) | Racionalia logika pagrįstas tikslinės vėžio terapijos modelis | |
| HK1207013A1 (en) | Catheter for photodynamic therapy | |
| EP3088001A4 (fr) | Agent thérapeutique pour tumeur maligne | |
| EP3044593A4 (fr) | Traitement du cancer | |
| EP2961412A4 (fr) | Cancérothérapie | |
| HK1209725A1 (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy | |
| EP2934500A4 (fr) | Polythérapie pour le traitement du cancer | |
| HK1218939A1 (zh) | 用於非小細胞肺癌療法的藥物選擇 | |
| HK1213475A1 (zh) | 用於癌症治療的 、卡培他濱和奧沙利鉑的組合 | |
| EP3058960A4 (fr) | Agent diagnostique pour un effet thérapeutique sur un cancer | |
| GB201518731D0 (en) | Tumour Therapy | |
| IL239231A0 (en) | Combined cancer treatment |